Figure 5
Effect of pro-Canakinumab on IL-1β-induced IL-6 expression. Human lung carcinoma cell line A549 (1.2 × 105) was treated with IL-1β (5 ng/mL, gray), and incubated with serum free medium (SFM) (black), Canakinumab (orange), pro-Canakinumab (blue), MMP-9 pre-incubated Canakinumab (pink) or MMP-9 pre-incubated pro-Canakinumab (purple) for 24 h. The supernatant was collected and the expression level of IL-6 was detected by human IL-6 DuoSet ELISA kit (R&D Systems, Minneapolis, MN, USA) according to the manufacturer’s protocol. All data are the mean ± SD of triplicate independent experiments (n = 3). Statistical significance was calculated by t test with *P < 0.05; **P < 0.01; ***P < 0.001 when compared between each indicated group.
